The results of our meta-analysis demonstrated that, compared with placebo, roxadustat increased Hb levels effectively and was associated with a remarkably higher rate of Hb response in NDD-CKD patients without increasing TEAEs. This evidence concerns the gene GSTM1 and chronic kidney disease.